The World Health Organization (WHO) continues to emphasize the importance of COVID-19 vaccination, recommending countries maintain immunization programs using updated vaccines that target current variants.
After reviewing recent evidence, the WHO’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) advises manufacturers to use monovalent vaccines based on the JN.1 or KP.2 lineages, or LP.8.1 as a suitable alternative. These updated formulations have shown robust neutralizing antibody responses against a range of circulating SARS-CoV-2 variants.
Despite challenges in global surveillance and data collection, JN.1-derived variants remain dominant in 2025. New vaccines using mRNA, protein-based, and adenovirus-vectored technologies have been rolled out in some countries and show added protection against severe disease.
WHO urges that vaccination should not be delayed in anticipation of newer versions. The organization is also calling for more research on immune responses, variant tracking, and vaccine effectiveness, especially in vulnerable populations.
No responses yet